Survanta Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to rising premature birth rates, increased awareness of neonatal respiratory distress syndrome, expansion of neonatal intensive care units, improved survival rates of preterm infants, wider clinical adoption of surfactant therapy.

The growth in the forecast period can be attributed to increasing focus on advanced neonatal care technologies, expansion of neonatal healthcare access in emerging markets, ongoing clinical research in lung maturation therapies, rising demand for early intervention treatments, improved neonatal drug delivery methods. Major trends in the forecast period include increasing use of surfactant replacement therapies, growing focus on neonatal respiratory care, expansion of nicu infrastructure globally, improved administration techniques for premature infants, enhanced clinical protocol standardization.

The increasing prevalence of premature births is expected to drive the growth of the Survanta market going forward. Premature births, defined as births occurring before 37 weeks of pregnancy, result in underdeveloped organs and heightened health risks for newborns. The rising prevalence of premature births is attributed to factors such as advanced maternal age, lifestyle choices, higher rates of chronic conditions, and the increased use of fertility treatments. Survanta is used to treat respiratory distress syndrome (RDS) in premature infants, a condition caused by insufficient surfactant production in the lungs, helping improve lung function and reduce complications. For instance, in April 2025, the Centers for Disease Control and Prevention reported a preterm birth rate of 10.41% in 2024. Therefore, the increasing prevalence of premature births is driving the growth of the Survanta market.

The growing number of infant hospital admissions is expected to propel the growth of the Survanta market. Rising hospital admissions among infants are due to higher rates of premature births, increased incidences of neonatal and respiratory conditions, improved survival rates requiring more complex care, and greater access to healthcare facilities. Survanta supports infants during hospitalization by treating RDS, enhancing lung function, and reducing the risk of complications. For instance, in May 2024, the Office for Health Improvement and Disparities reported that hospital admissions of infants under 14 days increased from 81.6 per 1,000 population in 2022 to 84.8 per 1,000 population in 2023. Therefore, the growing number of infant hospital admissions is driving the growth of the Survanta market.

Increasing investments in maternal and child health are expected to boost the growth of the Survanta market. Maternal and child health focuses on the well-being of women during pregnancy, childbirth, and postpartum, as well as the health and development of children, particularly in early life. Rising investments are driven by the need to reduce maternal and infant mortality, improve healthcare access, and support long-term social and economic development. Such investments ensure access to life-saving treatments like Survanta, helping reduce neonatal mortality from RDS. For instance, in September 2024, the American Hospital Association reported that the U.S. Department of Health and Human Services allocated over $558 million to maternal health initiatives, including $440 million for home visiting services and $118.5 million for CDC programs. Therefore, increasing investments in maternal and child health are driving the growth of the Survanta market.

Major companies operating in the survanta market are AbbVie Ltd.

North America was the largest region in the survanta market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the survanta market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the survanta market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the survanta market by increasing costs of imported pharmaceutical-grade lipids, sterile manufacturing supplies, cold-chain logistics systems, and specialized neonatal drug packaging. North America and Europe are most affected due to reliance on regulated pharmaceutical imports, while developing regions face higher access costs. These tariffs increase treatment expenses for neonatal care providers. However, they are also encouraging domestic pharmaceutical manufacturing, localized sourcing of medical inputs, and stronger regional supply chains for critical neonatal respiratory therapies.

The survanta market research report is one of a series of new reports that provides survanta market statistics, including survanta industry global market size, regional shares, competitors with a survanta market share, detailed survanta market segments, market trends and opportunities, and any further data you may need to thrive in the survanta industry. This survanta market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Survanta is a surfactant medication used to treat or prevent respiratory distress syndrome (RDS) in premature infants. It replaces the natural surfactant in the lungs, reducing alveolar surface tension, improving breathing, and enhancing oxygen exchange. The medication is administered directly into the lungs to support respiratory function and stability.

The primary indications for Survanta include respiratory distress syndrome (RDS), meconium aspiration syndrome (MAS), bronchopulmonary dysplasia (BPD), acute respiratory failure, and other related conditions. Respiratory distress syndrome (RDS) is common in premature infants whose lungs lack sufficient surfactant, leading to breathing difficulties and inadequate oxygenation. Survanta is distributed through hospital pharmacies, retail pharmacies, and public health clinics and is used in pediatric patients.

The survanta market consists of sales of surfactant delivery devices, neonatal respiratory care kits, syringes, and injection systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.